Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent sign ...
Diabetes patients taking an investigational drug from Eli Lilly saw significant reductions in their blood sugar and weight in ...
Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...
A new analysis represents the largest effort yet to systematically parse all the data from high-quality clinical trials on cannabis and mental health. The evidence is lacking.
Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI ...
A real-world analysis of patients receiving teclistamab prior to 2022 showed comparable outcomes to clinical trials and ...
The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major shift in the treatment paradigm, moving powerful bispecifi ...
SAN DIEGO--(BUSINESS WIRE)--SEQSTER PDM, Inc. (“SEQSTER”), the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, today ...
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...
Time burden and healthcare costs associated with docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating an androgen receptor pathway inhibitor (ARPI) –based ...
BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results